<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00389311</url>
  </required_header>
  <id_info>
    <org_study_id>CDC 200-2001-08015-02</org_study_id>
    <nct_id>NCT00389311</nct_id>
  </id_info>
  <brief_title>A Pilot Study for Toxicity Evaluation of HIV Rectal Microbicides</brief_title>
  <official_title>A Pilot Protocol to Determine the Effects of Chemical and Mechanical Stress on Rectal Permeability as a Surrogate for Toxicity Evaluation of Rectally Applied Microbicides</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Johns Hopkins University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Johns Hopkins University</source>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine if detectable changes in permeability of the lining&#xD;
      of the colon are caused by either application of HIV microbicide gels or medical procedures,&#xD;
      such as flexible sigmoidoscopy.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      It is not currently known if procedures used to observe the lining of the distal colon, such&#xD;
      as endoscopy with or without pinch biopsy, may cause mucosal trauma and thus alter colonic&#xD;
      permeability. Additionally, the application of topical HIV microbicides (to prevent HIV&#xD;
      transmission) and shearing forces associated with rectal intercourse might also adversely&#xD;
      affect the epithelial layer, and thus alter colonic permeability. In order to appropriately&#xD;
      interpret testing of the effects of topical HIV microbicides on the mucosal lining of the&#xD;
      distal colon, it is essential to understand whether these procedures themselves, adversely&#xD;
      affect the epithelial layer. If changes in permeability can be detected, this method may be&#xD;
      developed to help determine microbicide distribution/toxicity in early phase studies, thus&#xD;
      improving the selection of candidate microbicides for study in larger scale clinical trials.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>April 2007</start_date>
  <completion_date type="Actual">June 2009</completion_date>
  <primary_completion_date type="Actual">February 2008</primary_completion_date>
  <phase>Early Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>Single (Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Intra-subject comparison of urine and plasma concentrations of 99mTc-DTPA</measure>
    <time_frame>0-2 hours, 2-4 hours, 4-8 hours, 8-12 hours and 12-24 hours after introduction of the treatment assignment</time_frame>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">12</enrollment>
  <condition>HIV Infections</condition>
  <arm_group>
    <arm_group_label>Nonoxynol-9</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Gynol-II, 2% N-9, 5 mL</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Normosol-R</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Normosol-R, 5 mL, single administration, negative control</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Normosol with simulation, endoscopy and biopsy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Normosol-R, 5 mL following simulation, endoscopy and biopsy</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Normosol-R</intervention_name>
    <arm_group_label>Normosol with simulation, endoscopy and biopsy</arm_group_label>
    <arm_group_label>Normosol-R</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Nonoxynol-9</intervention_name>
    <arm_group_label>Nonoxynol-9</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Gastrointestinal instrumentation</intervention_name>
    <arm_group_label>Normosol with simulation, endoscopy and biopsy</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Greater than or equal to 21 years of age&#xD;
&#xD;
          -  Prior history of receptive anal intercourse (RAI)&#xD;
&#xD;
          -  Subjects must have a history of using commercially-available personal lubricants for&#xD;
             RAI.&#xD;
&#xD;
          -  Ability to provide signed informed consent.&#xD;
&#xD;
          -  Willingness to abstain from lubricant use and anal receptive intercourse for 48 hours&#xD;
             prior to and 48 hours after Phases A and B.&#xD;
&#xD;
          -  Willingness to use a single dose of rectally-applied N-9.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Mental handicap or impaired cognitive performance status as judged by the&#xD;
             investigator.&#xD;
&#xD;
          -  Coagulation abnormality which would put the subject at risk for bleeding as judged by&#xD;
             the Principal Investigator.&#xD;
&#xD;
          -  History of anorectal surgery within the last month or the presence of any anorectal&#xD;
             disease or condition that in the judgment of the investigator could affect&#xD;
             permeability of the rectal mucosa.&#xD;
&#xD;
          -  Presence of any painful anorectal conditions or anorectal lesions that would be tender&#xD;
             to manipulation.&#xD;
&#xD;
          -  History of occupational radiation exposure.&#xD;
&#xD;
          -  History of acute or chronic diarrhea defined as three or more loose stools per day.&#xD;
&#xD;
          -  History of any allergic response to rectal lubricants.&#xD;
&#xD;
          -  History of sleep apnea, or airway problems with previous sedation procedures.&#xD;
&#xD;
          -  History of significant adverse reaction to sedation medications.&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Edward Fuchs, PA-C, MBA</last_name>
    <role>Principal Investigator</role>
    <affiliation>The Johns Hopkins University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>The Johns Hopkins Hospital</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21287</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <results_reference>
    <citation>Fuchs EJ, Grohskopf LA, Lee LA, Bakshi RP, Hendrix CW. Quantitative assessment of altered rectal mucosal permeability due to rectally applied nonoxynol-9, biopsy, and simulated intercourse. J Infect Dis. 2013 May 1;207(9):1389-96. doi: 10.1093/infdis/jit030. Epub 2013 Jan 16.</citation>
    <PMID>23325915</PMID>
  </results_reference>
  <verification_date>January 2009</verification_date>
  <study_first_submitted>October 17, 2006</study_first_submitted>
  <study_first_submitted_qc>October 17, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 18, 2006</study_first_posted>
  <last_update_submitted>March 30, 2015</last_update_submitted>
  <last_update_submitted_qc>March 30, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 1, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Johns Hopkins University</investigator_affiliation>
    <investigator_full_name>Craig W. Hendrix</investigator_full_name>
    <investigator_title>Professor, Department of Medicine</investigator_title>
  </responsible_party>
  <keyword>Microbicide</keyword>
  <keyword>Safety</keyword>
  <keyword>HIV prevention</keyword>
  <keyword>HIV Seronegativity</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>HIV Infections</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Nonoxynol</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

